Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports
Go Back
View Our Subscription Options

Search

Descriptive Alt Text

Filters

Showing results 3,497–3,504 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Regeneron Pharmaceuticals Inc. EYLEA (aflibercept) - (SIENNA) Retinal vein occlusion NDA Filing Ongoing Intravitreal Opthalmic
Regeneron Pharmaceuticals Inc. C5 Combo (pozelimab and cemdisiran) Geographic atrophy Phase 3 Ongoing Subcutaneous Opthalmic
Regeneron Pharmaceuticals Inc. C5 Combo (pozelimab and cemdisiran) Paroyxsmal noctural hemoglobinuria Phase 3 Ongoing Subcutaneous Hematology
Regeneron Pharmaceuticals Inc. C5 Combo (pozelimab and cemdisiran) Paroyxsmal noctural hemoglobinuria Phase 3 Ongoing Subcutaneous Hematology
Regeneron Pharmaceuticals Inc. Libtayo (cemiplimab) combined with Fianlimab Melanoma Phase 3 Data Released Intravenous infusion Oncology
Regeneron Pharmaceuticals Inc. LIBTAYO (cemiplimab) Non-small cell lung cancer (NSCLC) Phase 3 Trial Discontinued intravenous Oncology
Regeneron Pharmaceuticals Inc. Fasinumab Osteoarthritis pain of the hip or knee Phase 3 Trial Discontinued Intravenous Orthopedic
Regeneron Pharmaceuticals Inc. REGN2222 Respiratory syncytial virus (RSV) Phase 3 Trial Discontinued Intramuscular Respiratory
1…436437438439440…553
Your trusted source for drug reimbursement data and buy-and-bill insights.
Platform
Resources
Tools
Search Drugs
Newsletter
Reimbursement updates, drug pricing news.
© 2026 BuyandBill.com, All Rights Reserved.
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association). CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.